Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.


Journal

International archives of allergy and immunology
ISSN: 1423-0097
Titre abrégé: Int Arch Allergy Immunol
Pays: Switzerland
ID NLM: 9211652

Informations de publication

Date de publication:
2020
Historique:
received: 05 10 2019
accepted: 07 10 2019
pubmed: 14 11 2019
medline: 14 1 2020
entrez: 14 11 2019
Statut: ppublish

Résumé

Although 4 mast cell mediators can be routinely measured, the results of initial testing to evaluate symptoms of mast cell activation have not been widely reported. We examined the results of mast cell mediator tests used to assess patients with mast cell activation symptoms during a 5-year time span. After excluding patients with alternative diagnoses, records of 108 patients were reviewed for initial mediator test results. Mediators included serum tryptase plus urinary N-methyl histamine (N-MH), leukotriene (LT)E4, and 11β-prostaglandin (PG) F2α or 2,3-dinor-11β-PGF2α (BPG). Most commonly, either a single measured elevation of 1 mediator (48.1%) or elevations of 2 (33.3%) mediators was found at baseline, during symptoms or at both time points. Elevated levels of a single mediator in order of frequency were: BPG > tryptase > LTE4 > N-MH, and for two mediators: BPG + tryptase (n = 16 cases) > BPG + LTE4 (n = 9) > BPG + N-MH (n = 6). Elevations in 3 mediators (n = 8) or 4 mediators (n = 2) were much less frequent. Monoclonal mast cell activation syndrome (n = 6), and systemic and cutaneous mastocytosis (n = 4) were also infrequent. Baseline plus symptom-associated tryptase values were obtained in only 7 patients. This survey suggests that elevations of 1 or 2 mediators are the most common (total 81.4% of cases) findings from initial tests for mast cell activation. Elevated levels of BPG were most commonly found both singly and in combination with other mediators, followed by the finding of elevated levels of tryptase. Baseline plus symptom-associated tryptase levels were measured in only a minority of patients.

Identifiants

pubmed: 31722348
pii: 000503964
doi: 10.1159/000503964
doi:

Substances chimiques

Methylhistamines 0
Leukotriene E4 75715-89-8
Dinoprost B7IN85G1HY
Tryptases EC 3.4.21.59
N-methylhistamine Y7QR253130

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-50

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Joseph H Butterfield (JH)

Division of Allergic Diseases and Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, Minnesota, USA, butterfield.joseph@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH